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Abstract
Background: Limited data on the prevalence and medical care of sickle cell disease (SCD) in Ger-
many are available. Here, we make use of a patient registry to characterize the burden of disease
and the treatment modalities for patients with SCD in Germany.
Procedure:AnationwideGerman registry for patientswith SCDdocuments basic data on diagno-
sis and patient history retrospectively at the time of registration. A prospective annual documen-
tation provides more details on complications and treatment of SCD. For the current analyses,
data of 439 patients were available.
Results:Most patients had homozygous SCD (HbSS 75.1%, HbS/𝛽-thalassemia 13.2%, and HbSC
11.3%). The median age at diagnosis was 1.9 years (interquartile range, 0.6-4.4 years), most
patients were diagnosed when characteristic symptoms occurred. Sepsis and stroke had affected
3.2% and 4.2% of patients, respectively. During the first year of observation, 48.3% of patients
were admitted to a hospital and 10.1% required intensive care. Prophylactic penicillin was pre-
scribed to 95.6% of patients with homozygous SCDorHbS/𝛽 thalassemia below the age of six and
hydroxycarbamide to 90.4% of patients above the age of two years. At least one annual transcra-
nial Doppler ultrasoundwas documented for 74.8% of patients between 2 and 18 years.
Conclusion: With an estimated number of at least 2000, the prevalence of SCD in Germany
remains low. Prospectively, we expect that the quality of care for children with SCD will be fur-
ther improved by an earlier diagnosis after the anticipated introduction of a newborn screening
program for SCD.
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1 INTRODUCTION
Sickle cell disease (SCD) is a multiorgan disorder resulting in signifi-
cant morbidity andmortality.1,2 Through prophylactic and therapeutic
interventions such as parent education,3 vaccinations,4 antibiotic
prophylaxis,5 hydroxycarbamide treatment6 and red blood cell
transfusion,7 survival during childhood has continuously improved.8
In Germany, SCD exclusively affects immigrants from endemic
areas and their descendants, especially from Africa and the Middle
East.9,10 Admission diagnosis data provide an estimate of the increas-
ing frequency of SCD and of its complications in Germany.10 However,
more detailed epidemiological data are required to document the bur-
den of disease, to identify shortcomings in patientmanagement, and to
improvepatient care. In addition, healthpolicydecision-making, e.g., on
the implementation of a newborn screening for SCDor on the licensing
of hydroxycarbamide for infants, needs to be supported by “real-world
evidence.” Several patient registriesworldwide have already answered
many clinical questions concerning SCD.8,11–14 However, these data
cannot be directly transferred to patients living in Germany, who likely
differ from those living elsewherewith regard to the genetic and social
background. For these reasons, a registry for patients with SCD was
established by the German Society of Pediatric Oncology and Hema-
tology (GPOH). Here, we report the first results from this registry.
2 METHODS
2.1 Registry design
The nationwide SCD registry records retrospective and prospective
data on patients with SCD across multiple centers. Primarily, all pedi-
atric centers organized in the German Society for Pediatric Oncology
and Hematology and three internal medicine centers were invited to
join the registry. In total, 61 centers were approached, 38 committed
to participate and 22were actively recruiting at the time of data cutoff.
New centers may join the registry at any time. Key inclusion criterion
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was the diagnosis of SCD (both homozygous and compound heterozy-
gous). Heterozygous carriers of theHbS trait were excluded. The study
was approved by the institutional review board of theMedical Faculty
of Heidelberg University (S-416/2014) and performed according to
the Declaration of Helsinki. Written informed consent from patients
or legal guardians, respectively, was obtained. The first patient was
registered inNovember 2015. Data cutoff for this publicationwas July
4, 2019. Apart from the registry, the SCD consortiummandated by the
GPOH coordinates several other activities in support of the registry.
These include treatment guidelines for SCD,15 creation of a reference
network to offer advice to physicians with limited experience with
SCD, pilot projects in newborn screening for SCD, and educational
events. The registry is filed with ClinicalTrials.gov (NCT03327428).
2.2 Care for SCD
The registry is a purely observational study that does not regulate
patient treatment. However, national treatment guidelines15 recom-
mend basic health care measures for SCD, such as parental education,
vaccinations, the use of antibiotic prophylaxis or TCD screening as do
international treatment guidelines.16,17 In Germany, everybody is cov-
ered under an obligatory health insurance system, regardless of their
employment status. New immigrants who are asylum seekers have
access to medical treatment for acute conditions as well as vaccina-
tions. After a waiting period of 15 months, they become eligible for
the obligatory health insurance coverage, which includes free access
to approved medications. Currently, 60 centers with expertise in pedi-
atric hematology offer care for patients with SCD, but not all cen-
ters are equipped for TCD screening. Adults with SCD are frequently
taken care of by general practitioners, most hematologists follow few
patients only.
2.3 Data collection
The registry continues collecting data prospectively without fixed end
date. Participating centers enter data via “remote data entry” into elec-
tronic case report forms that have been designed using the electronic
data capture software Marvin (XClinical GmbH, Munich, Germany).
At the time of registration, basic data including date of birth, date and
circumstances of diagnosis, genotype, country of origin, blood group,
and patient’s past medical history are reported. Starting from the date
of registration, annual follow-ups prospectively document details of
SCD-related complications (see Supporting Information Table S1),
laboratory parameters, and treatment that have been collected in the
previous 12 months. Data verification was by plausibility check but
not by source data verification. The data that support the findings of
this study are available on request from the corresponding author. The
data are not publicly available due to privacy or ethical restrictions.
2.4 Statistical analysis
Periodic analysis and reporting are conducted annually and include
analyses specified by a cutoff date. The present report is based on an
interim analysis with all available data until the cutoff date of July 4,
2019.
In this observational study, no formal statistical hypothesis was
specified in the study protocol. The sample size is not statistically
powered for hypothesis testing, and the statistical analysis focuses on
descriptive and exploratory techniques.
3 RESULTS
Until the cutoff date, 22 centers in Germany registered a total of 439
patients with SCD. Two centers (Hamburg, Berlin) contributed each at
least 50 patients, ten more centers at least 10, thus documenting that
SCD patients are widely distributed across the country. Two-hundred
twenty-four patients (51%) were female, and 215 (49%) were male.
Genotypes, countries of origin, age at diagnosis, and age at registration
are presented in Table 1. One-hundred seventy-two (90.1%) of 191
patients with SCD aged 6 to 16 years attend regular schools.
3.1 SCD results in relevantmorbidity
As expected, at the time of registration, more than two thirds of
patients had already experienced at least one pain crisis requiring hos-
pitalization, more than one quarter had suffered from acute chest syn-
drome (Table 2). These numbers were lower in patients with HbSC
disease compared with homozygous SCD. Stroke and sepsis were
reported in the history of 4.2% and 3.2% of all patients, respectively.
During the first year of observation (Table 3), 201 (48.4%) of 415
evaluable registry patients with SCD were treated as inpatients,
20 (10.2%) of 196 evaluable patients required intensive care. The
totals of evaluable patients vary because the number of missing values
differs, leaving room for a reporting bias if the number of evaluable
patients is considerably lower than the total of 439. Themost frequent
reason for hospitalization was acute pain (154 of 413 patients, 37.3%),
followed by acute chest syndrome. These numbers did not change
during the second and third years of follow-up (Supporting Informa-
tion Table S2). On average, patients were admitted 0.7 times per year
for pain (range, 0-20). Hospital admissions for pain crisis documented
during the first annual follow-up in the SCD registry (283 in n = 406
patients) represent 22.3% of the 1269 hospital admissions that
have been reported by hospitals with principal diagnosis “SCD with
crises”(ICD codeD57.0) in 2017 according to the nationwide statistics
of theGerman Federal Statistical Office.10,18 If the number of hospital-
izations in the registry was representative for all patients with SCD in
Germany, theminimum total number of patients with SCD in Germany
could be estimated to be at least 2000. However, in adult patients
treated in hospital, SCD frequently is a secondary, not a principal, hos-
pital diagnosis. Because adults are underrepresented in our registry,
the real number of patients with SCD may considerably exceed this
approximation. Further, the total number of patients may be underes-
timated because patients withmild diseasemay not be captured.
The overall incidence of acute chest syndrome (72 episodes in 679
observation years) was comparable to that in the cooperative study of
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TABLE 1 Patient and disease characteristics
Genotypes (n= 425)
HbSS 319 (75.1%)
HbS/𝛽0thal 27 (6.4%)
HbS/𝛽+thal 29 (6.8%)
HbSC 48 (11.3%)
Others: HbS/OArab 1 (0.2%), HbS/HPFH 1 (0.2%)
Region/country of origin*
(for each patient, country of origin of both parents is reported; n= 824)
Africa (66.8%) Nigeria 170 (20.6%)
Ghana 140 (17.0%)
Togo 48 (5.8%)
Angola 42 (5.1%)
Cameroon 34 (4.1%)
Guinea 23 (2.8%)
Congo 21 (2.6%)
Sierra Leone 12 (1.5%)
Other 60 (7.3%)
Asia (21.9%) Lebanon/Palestine 61 (7.5%)
Syria 41 (5.0%)
Turkey 32 (3.9%)
Iraq 25 (3.0%)
Other 21 (2.5%)
Europe (without Turkey) 19 (2.3%)
America 14 (1.7%)
Unknown 53 (6.4%)
Age at diagnosis/at registration
<1 year 1-5 years 6-11 years 12-17 years >17 years
At diagnosis (n= 379) 129 (34%) 189 (49.9%) 44 (11.6%) 13 (3.4%) 4 (1.1%)
At registration (n= 438) 14 (3.2%) 108 (24.7%) 155 (35.4%) 92 (21.0%) 69 (15.8%)
Circumstance of diagnosis (n= 351)
Newborn screening Positive family
history
Routine checkup Symptoms Incidental
finding
Others
18 (5.1%) 76 (21.7%) 5 (1.4%) 202 (57.5%) 34 (9.7%) 16 (4.6%)
∗Only countries contributing> 10 to the countries of origin.
TABLE 2 Medical history prior to registration: SCD-associated complications by genotype
HbSS HbS 𝜷0thal HbS 𝜷+thal HbSC Total
Genotype n= 319 n= 27 n= 29 n= 48 n= 425*
Severe pain crisis** 221 (71.1%) 17 (65.4%) 21 (72.4%) 24 (53.3%) 285 (69.0%)
Acute chest syndrome 102 (33.3%) 2 (8.7%) 6 (20.7%) 8 (18.2%) 118 (29.2%)
Splenic sequestration 42 (13.8%) 7 (29.2%) 7 (25.9%) 0 56 (14.0%)
Splenectomy 40 (12.8%) 9 (36.0%) 6 (20.7%) 0 55 (13.3%)
Aplastic crisis 28 (9.4%) 3 (13.0%) 5 (17.2%) 5 (11.4%) 42 (10.6%)
Stroke 15 (5.0%) 2 (8.3 %) 0 0 17 (4.2%)
Sepsis 12 (3.9%) 0 1 (3.4) 0 13 (3.2%)
Reaction to red blood cell
transfusion**
5 (1.7%) 0 0 0 5 (1.3%)
∗Two patients with genotypes HbS/OArab andHbS/HPFHwere excluded from this table; percentages were calculated from nonmissing values only.
∗∗Resulting in hospital admission.
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TABLE 3 SCD-associated complications by genotype, first annual follow-up
HbSS HbS 𝜷0thal HbS 𝜷+thal HbSC Total
Genotype n= 304 n= 26 n= 29 n= 45 n= 406a
Severe pain crisisb 112 (36.7%) 10 (38.5%) 14 (48.3%) 10 (22.2%) 147c (36.1%)
Acute chest syndrome 37 (12.1%) 1 (3.8%) 3 (10.3%) 3 (6.7%) 44 (10.8%)
Splenic sequestration 4 (1.3%) 2 (7.7%) 0 0 6 (1.5%)
Splenectomy 8 (2.6%) 1 (3.8%) 0 0 9 (2.2%)
Aplastic crisis 3 (1.0) 0 1 (3.4%) 3 (6.7%) 8c (2.0%)
Stroke 1 (0.3) 0 0 0 1 (0.2)
Sepsis 3 (1.0%) 0 0 0 3 (0.7%)
Reaction to red blood cell
transfusionb
0 1 (3.8%) 1 (3.4%) 0 2 (0.5%)
aPatients with documented genotype and first annual examination, percentages were calculated from nonmissing values only.
bResulting in hospital admission.
cOne patient with genotype HbS/HPFH experienced both pain crisis and aplastic crisis; one patient with genotype HbS/OArab had not experienced compli-
cations related to SCD.
SCD.19 Above the age of one year, the frequency of hospitalization for
pain and acute chest syndrome did not changewith age.
Three patients died of SCD-related complications, all male and
genotype HbSS: one patient (age 7 years) from streptococcal sep-
sis, one (age 40) from heart failure with siderosis, and one (age
11) from cerebral venous sinus thrombosis, intracranial bleeding and
pulmonary embolism. One additional patient (male, HbSS, age 6) died
from pulmonary complications and viral infection (EBV, Boca) on
day 100 after allogeneic stem cell transplantation from a matched
unrelated donor.
3.2 Treatment of sickle cell disease
Almost all children up to the age of five years with the genotypes
HbSS and HbS 𝛽0thal were prescribed antibiotic prophylaxis with
penicillin V (95.6%). The only currently available disease-modifying
drug hydroxycarbamide is licensed in Europe for use in children with
SCD with an age of two years and older. Close to 80% of all reg-
istry patients were prescribed hydroxycarbamide, 90.4% of patients
above the age of twowith either HbSS or HbS 𝛽0thal genotypes. These
numbers by far exceed those of other recent registry cohorts.11,12
Patientswithout hydroxycarbamide had fewer pain crises or chest syn-
dromes (on average, 0.3/year in 111 patient years, SD 0.6) as com-
pared with patients on hydroxycarbamide (0.8/year in 554 patient
years, SD 1.6), indicating that only mildly affected patients did not
receive hydroxycarbamide. The high proportion of patients prescribed
hydroxycarbamide is reflected in HbF levels. Adult patients with geno-
type HbSS had a mean HbF level of 12.5% (SD 8.2%, n = 11), more
than twice that reported for hydroxycarbamide-naïve patients ofWest
African origin.20,21 This relation holds true for patients of all ages
both of African origin (n = 105, mean HbF 17.6%, SD 15.3) and of
non-African origin (n = 48, mean HbF 19.8%, SD 16.5), indicating
that due to the effect of hydroxycarbamide, the HbF levels in the
registry patients are higher than in hydroxycarbamide-naïve patients
from Jamaica and similar to Indian patients of a comparable age
distribution.22
The high proportion of patients prescribed antibiotic prophylaxis
and hydroxycarbamide documents good compliance with current
guidelines.15,17 However, although the rate of transcranial Doppler
(TCD) ultrasounds usage (74.8% of patients with an indication) com-
pares favorably with historic cohorts,13,23 this important diagnostic
procedure is still underused.
One hundred six of 413 patients (25.7%) received red blood cell
transfusions, 84 (20.3%) for acute complications, 19 (4.6%) as a
“chronic” transfusion program, and 3 (0.7%) had both chronic and
emergency transfusions.
Twenty-three patients received 24 allogeneic stem cell trans-
plantations. All patients transplanted from a matched sibling donor
(n = 15) were alive without SCD and without GvHD at last contact.
Ten of these had at least one year of follow-up. Of the eight patients
having received allogeneic stem cell transplantation from a matched
unrelated donor, one patient died and one was transplanted a second
time for treatment-induced myelodysplastic syndrome after graft
failure one year after his first transplant. Of the remaining six patients,
follow-up is below one year in five.
3.3 Patients with an early diagnosis tend to have
fewer vaso-occlusive crises
Because SCD is not a target disease of the general newborn screening
in Germany, most of the registered patients were diagnosed later than
the first year of life after symptoms of SCD had occurred. In order
to tentatively assess within the limitations of a retrospective registry
whether an early diagnosis and subsequent treatment results in fewer
complications, we defined two groups of patients. If patients were
diagnosed within the first six months of life before the onset of symp-
toms (either because of positive family history, newborn screening, or
incidental finding), they were categorized as being diagnosed “early”
(n = 55). Patients diagnosed with symptoms of SCD or after the age
of six months were categorized as being diagnosed “late” (n = 325).
The proportion of patients with a history of pain crises was higher in
the “late” diagnosis group compared with the “early” diagnosis group
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(69.6% vs 53.7%, P(Fisher) = 0.03). As the “early diagnosis group” was
younger (mean age at registration 6.4 years) compared with the “late
diagnosis group” (10.8 years), this comparison is skewed by differing
age distributions. While the patients were followed in the registry, the
frequency of complications (hospitalization for acute pain crises or
chest syndrome) in the early diagnosis group did not differ significantly
from that in the late diagnosis group (mean 0.5/year in patients with
early diagnosis vs 0.8/year in patients with late diagnosis; standard
deviation 1.0 and 1.6, respectively). These findings suggest that our
patient registry may currently not be suitable to show the advan-
tages of newborn screening, either because of the limited number
of registered patients or, more likely, because of a bias against early
and potentially fatal events in patients who have not been diagnosed
early.
4 DISCUSSION
We set up a nationwide registry for SCD patients living in Germany, a
country that has recently accommodateda largenumberof immigrants
from regions with high prevalence of SCD.
On the basis of the insurance data documenting the total frequency
of hospital admissions10,18 and the average number of admissions for
pain crisis per patient documented here, we estimate the national Ger-
man SCD registry to currently cover up to 25% of all patients living
with SCD in the country. Further, the registry demonstrates that the
contributing centers generally treat their patients according to current
guidelines, which results in a profile of morbidity and mortality that is
likely comparablewith that of higher incidence countries in Europe and
North America.
In comparison with other European countries, the German registry
data reveal two unique characteristics: First, the diagnosis is made
at a relatively old age and mostly related to the occurrence of symp-
toms. This challenge will likely be addressed by the introduction of
a newborn screening for SCD in Germany, which is expected to be
introduced in 2021. Second, the proportion of patients treated with
hydroxycarbamide is far higher than reported in any SCD registry so
far,11,12 consistent with current national guidelines.15 We assume that
the comprehensive use of hydroxycarbamide is a characteristic of the
mostly academic centers participating in the registry but may not be a
nationwide phenomenon.
Our study suffers from several limitations that are inherent to the
design of a voluntary registry. Although 38.2% patients admitted to
German hospitals for SCD were age 20 or above,10 only 15.8% of our
registry patients are adults. This bias toward younger patients is due
to the fact that primarily large pediatric centers contributed to the
registry. Unfortunately, patients with SCD who are taken care of by
family physicians or at smaller institutions are much more difficult to
enroll and require further efforts until a near to complete enrollment
of all patients with SCD can be achieved. Although the total number
of patients with SCD in Germany is not known, we estimate the total
number of patients with SCD to be at least 2000 in Germany for 2017.
With regard to severe complicationsof SCD, themost important limita-
tionofour registry is the lackof auniversal newborn screening for SCD.
The fact that most patients were diagnosed with SCDwhen symptoms
occurred raises the concern of lethal complications before the diagno-
sis of SCD is made. Children dying from complications of SCD before
the diagnosis is made cannot be enrolled in the registry, thus the num-
ber of severe complications may be underestimated. Similar concerns
relate to patients arriving in Germany as refugees, typically without
documentation of their medical history.10,24 Although we know that
the number of patientswith SCDhas increasedbymore than30%after
2013,10 we do not know how many of the registry patients were born
in Germany and how many arrived after having suffered from SCD in
their home country or in another health care system.
Despite the obvious limitations, this registry systematically gathers
nationwide data on SCD and its treatment for Germany. In comparison
with a previous registry,25 both the number of enrolled patients and
the total of patientswith SCD inGermany have approximately doubled
since 2005. Although the proportion of patients treated with hydroxy-
carbamide has increased more than threefold compared with 2005
and antibiotic prophylaxis is offered> 95% of preschool children, TCD
measurements are still not used in every patient in need.We conclude
that the physicians that contributed to this registry, mostly pediatri-
cians, are aware of current treatment guidelines. However, the incom-
plete availability of TCD screening due to the lack of physicians with
expertise in this technique, and most importantly the late diagnosis
due to the lack of a newborn screening for SCD preclude treatment
according to international standards. In order to improve medical care
for patients with SCD, the most important measures are a newborn
screening program that is expected to be introduced in 202126 and a
TCD training program for physicians.
Patient registries, together with concomitant efforts such as physi-
cian training on treatment guidelines or establishing newborn screen-
ing programs for SCD, are essential for a comprehensive national SCD
management in countries where SCD has only recently been recog-
nized as a challenge.27 However, an optimal care will only be achieved
if a network of both pediatric and internal medical centers is dedicated
to offer routine follow-up and emergency treatment for patients with
SCD.
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